SYNkinase: Your first choice for small molecule inhibitors


SYN-1230 | CAS 1217486-61-7

Alpelisib (BYL719) is a selective PI3Kα inhibitor with IC50 of 5 nM. It has minimal effect on PI3K isoforms. Alpelisib exhibits favourable pharmacokinetics and excellent oral bioavailability in animal models. In xenografts using nude mice, it showed dose-dependent effect of tumour inhibition. In a phase Ib study, it showed synergistic anti-tumor activity with endocrine therapy against ER+/PIK3CA mutated breast cancer cells.

In stock
Technical Data
Cas 1217486-61-7
Alternative Names BYL719 , NVP-BYL719
Salt wt. N/A
References Ref. 1
Ref. 2
Api wt. 441.47
Formula C19H22F3N5O2S
Related Pathways
Purity >95%

Add to Cart

* Required Fields